I det poolede MEDAL- program stoppede 0, 3% af de patienter, der fik etoricoxib, og 2, 7% af de patienter, der fik diclofenac på grund af leverrelaterede hændelser.
In the pooled MEDAL Program, 0.3% of patients on etoricoxib and 2.7% of patients on diclofenac discontinued due to hepatic-related adverse experiences.